Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Shares Purchased by JPMorgan Chase & Co.

JPMorgan Chase & Co. grew its position in shares of Nautilus Biotechnology, Inc. (NASDAQ:NAUT) by 309.9% during the fourth quarter, HoldingsChannel reports. The firm owned 145,937 shares of the company’s stock after buying an additional 110,334 shares during the period. JPMorgan Chase & Co.’s holdings in Nautilus Biotechnology were worth $245,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Barclays PLC grew its holdings in Nautilus Biotechnology by 79.6% during the 3rd quarter. Barclays PLC now owns 106,174 shares of the company’s stock valued at $303,000 after purchasing an additional 47,059 shares in the last quarter. SG Americas Securities LLC increased its position in shares of Nautilus Biotechnology by 56.3% during the fourth quarter. SG Americas Securities LLC now owns 27,483 shares of the company’s stock worth $46,000 after acquiring an additional 9,904 shares during the last quarter. Palumbo Wealth Management LLC increased its position in shares of Nautilus Biotechnology by 45.4% during the fourth quarter. Palumbo Wealth Management LLC now owns 28,475 shares of the company’s stock worth $48,000 after acquiring an additional 8,888 shares during the last quarter. Finally, Virtu Financial LLC acquired a new position in shares of Nautilus Biotechnology in the fourth quarter worth about $28,000. 50.71% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Guggenheim set a $2.50 price objective on Nautilus Biotechnology in a report on Friday, February 28th.

Insider Transactions at Nautilus Biotechnology

In other news, CEO Sujal M. Patel acquired 53,300 shares of Nautilus Biotechnology stock in a transaction that occurred on Wednesday, March 19th. The shares were purchased at an average cost of $0.99 per share, for a total transaction of $52,767.00. Following the completion of the purchase, the chief executive officer now directly owns 10,117,788 shares of the company’s stock, valued at $10,016,610.12. This trade represents a 0.53 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 40.50% of the company’s stock.

Nautilus Biotechnology Price Performance

Shares of NAUT stock opened at $0.68 on Friday. The firm has a fifty day moving average of $0.91 and a two-hundred day moving average of $1.67. The firm has a market cap of $85.45 million, a P/E ratio of -1.21 and a beta of 1.39. Nautilus Biotechnology, Inc. has a 1-year low of $0.66 and a 1-year high of $3.09.

Nautilus Biotechnology (NASDAQ:NAUT) last posted its quarterly earnings results on Tuesday, April 29th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.01. On average, sell-side analysts expect that Nautilus Biotechnology, Inc. will post -0.57 EPS for the current year.

Nautilus Biotechnology Profile

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.